Clinical trials: Anticoagulant
Atrial Fibrillation
Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation
Use of new oral anticoagulants (NOAC) in patients before and after catheter based pulmonary vein isolation (PVI) is still controversial.
- Trial name
- NCT02569255
- Testing
- Pulmonary venous ostia isolation
- Volunteers
- 234 people
- Sponsor
- Private Hospital Heart Center Varde
Pulmonary Embolism
Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy
This study compares two blood thinners which are both accepted standard cares, fondaparinux and unfractionated heparin (UFH). These drugs are used to prevent the growth of existing blood clots and formation of additional blood…
- Trial name
- NCT00377091
- Testing
- Fondaparinux
- Where
- United States
- Sponsor
- University of Minnesota
Pulmonary Embolism, Embolism
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial.
- Conditions
- Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases
- Trial name
- SAFE-SSPE (NCT04263038)
- Testing
- Rivaroxaban
- Where
- 40 sites in Belgium, Canada and 3 more
- Volunteers
- 276 people
- Sponsor
- Drahomir Aujesky
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of…
- Trial name
- CER3 (NCT03570047)
- Where
- Japan
- Volunteers
- 73,989 people
- Sponsor
- Pfizer
Antiphospholipid Syndrome (APS), Cohort Study
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier…
- Conditions
- Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events
- Trial name
- DOWAPS (NCT06884384)
- Testing
- Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml), Completion of a questionnaire on compliance with anticoagulant treatment, Completion of a questionnaire on satisfaction with treatment anticoagulant
- Where
- 13 sites in France
- Volunteers
- 310 people
- Sponsor
- Central Hospital, Nancy, France
Cerebrovascular Stroke, Intracranial Hemorrhages
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore…
- Conditions
- Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases
- Trial name
- NCT03772457
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study
Several new oral direct anticoagulants have been recently marketed. However, only a few, limited, studies have provided data about the pharmacology of new oral direct anticoagulants in older persons.
- Trial name
- ADAGE (NCT02464488)
- Testing
- Plasma drug concentrations
- Where
- 2 sites in France
- Volunteers
- 232 people
- Sponsor
- Hôpital Charles Foix
Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs)
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
This registry will make it possible to collect large-scale data on SAPL patients, particularly those treated with DOACs, in order to better assess the frequency of thrombotic and hemorrhagic events in this population of…
- Conditions
- Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs), Thrombotic and Bleeding Events, Safety
- Trial name
- OBSTINATE 2 (NCT06929182)
- Testing
- "non-high risk" thrombotic APS patients treated with DOAC
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Central Hospital, Nancy, France
Atrial Fibrillation, Anticoagulants and Bleeding Disorders
Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy
Up to 5% of Atrial Fibrillation (AF) patients may have or develop contraindications to use oral anticoagulation (OAC). Randomized controlled trial (RCT) data suggest that Left Atrial Appendage Occlusion (LAAO) may provide a…
- Trial name
- COMPARE-LAAO (NCT04676880)
- Testing
- Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)
- Where
- 14 sites in Netherlands
- Volunteers
- 609 people
- Sponsor
- R&D Cardiologie
Aortic Dissection, Factor X Inhibition
The Effect of the CytoSorb® Filter to Remove Anticoagulants From the Circulation During Emergency Surgery for Aortic Dissection
The direct oral anticoagulants (DOACs) and particularly the FXa inhibitors are a concern in patients presenting with type A aortic dissection as this may contribute to severe bleeding complications.
- Trial name
- Citron (NCT05235178)
- Where
- Norway
- Volunteers
- 11 people
- Sponsor
- Oslo University Hospital
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of…
- Trial name
- PADIS TVP (NCT00740493)
- Testing
- warfarin
- Where
- 14 sites in France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation
The Effectiveness of Interactive Nursing Education Program Through Health Belief Model Based and Informative Technology-assisted on Atrial Fibrillation Patients Receiving Oral Anticoagulant
This study examined patients on taking oral anticoagulants (OACs) are often prescribed for Atrial fibrillation (AFib) to determine the effectiveness of a multiple interactive health education program, which was developed based on…
- Trial name
- NCT05145634
- Testing
- Patient education related oral anticoagulants (OACs)
- Volunteers
- 150 people
- Sponsor
- Chang Gung Memorial Hospital
Covid19
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in…
- Trial name
- XACT (NCT04640181)
- Testing
- Enoxaparin, Rivaroxaban
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. David's HealthCare
Atrial Fibrillation (AF)
Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
The goal of this clinical trial is to learn if Rebamipide effective in gastroprotection in patients with atrial fibrillation who are treated with Direct Oral Anticoagulants (DOACs).
- Trial name
- REGATA (NCT07354230)
- Testing
- Rebamipide 100mg, Pantoprazole
- Where
- Russia
- Volunteers
- 210 people
- Sponsor
- Pirogov Russian National Research Medical University
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Atrial Fibrillation, Stroke
Amplatzer Amulet LAAO vs. NOAC
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- CATALYST (NCT04226547)
- Testing
- Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
- Where
- 127 sites in United States, Australia and 14 more
- Volunteers
- 2,650 people
- Sponsor
- Abbott Medical Devices
Anticoagulant-induced Bleeding, Warfarin Sodium Causing Adverse Effects in Therapeutic Use
AI-based Social Software to Manage wARfarin Therapy
The investigators have demonstrated that social software could improve warfarin therapy quality by Human management. however,the efficiency of management will decline if patients' number expands huge.
- Trial name
- AI-SMART (NCT03870581)
- Testing
- AI-based social software management model, Human-based social software management model
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Respiratory Insufficiency, Circulatory Failure
Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an…
- Conditions
- Respiratory Insufficiency, Circulatory Failure, Thromboembolism, Bleeding
- Trial name
- CASUAL-ECMO (NCT06442267)
- Testing
- Enoxaparin Injectable Solution, Argatroban, 1 Mg/mL Intravenous Solution, Unfractionated heparin
- Where
- Austria
- Volunteers
- 90 people
- Sponsor
- Medical University of Vienna